RCAMU
BIIB icon

Rothschild & Co Asset Management US’s Biogen BIIB Stock Holding History

Rothschild & Co Asset Management US’s Portfolio BIIB Stock Details BIIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-30,925
Closed -$8.27M – 302
2020
Q2 		$8.27M Sell
30,925
-47,639
-61% -$14.3M 0.12% 231
2020
Q1 		$24.9M Sell
78,564
-34,019
-30% -$10.3M 0.39% 93
2019
Q4 		$33.4M Sell
112,583
-43,249
-28% -$12M 0.35% 117
2019
Q3 		$36.3M Buy
155,832
+10,041
+7% +$2.34M 0.39% 99
2019
Q2 		$34.1M Sell
145,791
-10,876
-7% -$2.51M 0.36% 112
2019
Q1 		$37M Sell
156,667
-1,848
-1% -$582K 0.4% 91
2018
Q4 		$47.7M Sell
158,515
-847
-0.5% -$270K 0.58% 39
2018
Q3 		$56.3M Buy
159,362
+3,478
+2% +$1.2M 0.58% 37
2018
Q2 		$45.2M Buy
155,884
+363
+0.2% +$102K 0.49% 54
2018
Q1 		$42.6M Buy
155,521
+35,039
+29% +$10.9M 0.47% 60
2017
Q4 		$38.4M Sell
120,482
-23,057
-16% -$7.4M 0.41% 87
2017
Q3 		$44.9M Buy
143,539
+79,334
+124% +$23.5M 0.49% 59
2017
Q2 		$17.4M Sell
64,205
-4,168
-6% -$1.1M 0.2% 196
2017
Q1 		$18.7M Sell
68,373
-1,542
-2% -$436K 0.21% 187
2016
Q4 		$19.8M Buy
69,915
+3,697
+6% +$1.1M 0.25% 158
2016
Q3 		$20.7M Sell
66,218
-48,443
-42% -$14.3M 0.36% 97
2016
Q2 		$27.7M Sell
114,661
-14,741
-11% -$3.88M 0.5% 47
2016
Q1 		$33.7M Buy
129,402
+277
+0.2% +$73.2K 0.63% 41
2015
Q4 		$39.6M Buy
129,125
+72,843
+129% +$20.9M 0.72% 31
2015
Q3 		$16.4M Buy
56,282
+1,382
+3% +$456K 0.32% 105
2015
Q2 		$22.2M Buy
54,900
+216
+0.4% +$86.7K 0.41% 70
2015
Q1 		$23.1M Buy
54,684
+9,128
+20% +$3.6M 0.44% 69
2014
Q4 		$15.5M Buy
45,556
+606
+1% +$196K 0.31% 105
2014
Q3 		$14.9M Buy
44,950
+39
+0.1% +$12.9K 0.32% 93
2014
Q2 		$14.2M Buy
44,911
+1,544
+4% +$465K 0.29% 104
2014
Q1 		$13.3M Sell
43,367
-26,971
-38% -$8.56M 0.3% 107
2013
Q4 		$19.7M Sell
70,338
-1,001
-1% -$259K 0.44% 60
2013
Q3 		$17.2M Sell
71,339
-4,638
-6% -$1.04M 0.37% 81
2013
Q2 		$16.4M Buy
+75,977
New +$16.2M 0.38% 73

Other funds holding BIIB

Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Rothschild & Co Asset Management US's BIIB Position: Q3 2020 in Review

Rothschild & Co Asset Management US sold out of Biogen (BIIB) in Q3 2020, closing a stake of 30,925 shares — an estimated $8.27M sold.

Rothschild & Co Asset Management US first reported a position in BIIB in Q2 2013 and held it in 29 quarters. The position peaked at $56.3M in Q3 2018. 1,051 funds tracked by Wall St. Rank hold BIIB as of Q3 2020.

  • Rothschild & Co Asset Management US reported no remaining Biogen position as of Q3 2020 after selling out during the quarter.
  • Rothschild & Co Asset Management US sold 30,925 Biogen shares in Q3 2020, an estimated $8.27M.
  • Rothschild & Co Asset Management US first reported a position in Biogen in Q2 2013 and held it in 29 quarters.
  • Rothschild & Co Asset Management US's Biogen position peaked at $56.3M in Q3 2018.
  • 1,051 funds tracked by Wall St. Rank held Biogen as of Q3 2020.

Based on Rothschild & Co Asset Management US's 13F filing for Q3 2020, filed 9 Nov 2020.